Juno Therapeutics

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.
Company Growth (employees)
Type
Public
HQ
Seattle, US
Founded
2013
Size (employees)
548 (est)+3%
Juno Therapeutics was founded in 2013 and is headquartered in Seattle, US

Key People at Juno Therapeutics

Hans Bishop

Hans Bishop

CEO

Juno Therapeutics Office Locations

Juno Therapeutics has offices in Seattle, Washington, Bothell, Waltham and in 2 other locations
Seattle, US (HQ)
300 307 Westlake Ave N
Show all (6)

Juno Therapeutics Data and Metrics

Juno Therapeutics Financial Metrics

Juno Therapeutics's revenue was reported to be $19.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

19.3 m

Net income (Q1, 2017)

(82.2 m)

EBIT (Q1, 2017)

(84.3 m)

Market capitalization (22-Aug-2017)

2.9 b

Cash (31-Mar-2017)

205.7 m
Juno Therapeutics's current market capitalization is $2.9 b.
USDFY, 2015FY, 2016

Revenue

18.2 m79.4 m

Revenue growth, %

336%

R&D expense

46.2 m264.3 m

General and administrative expense

4.2 m70.7 m

Operating expense total

50.5 m335 m

EBIT

(51.7 m)(255.6 m)

EBIT margin, %

(284%)(322%)

Pre tax profit

(51.8 m)(256.2 m)

Income tax expense

2.8 m10.7 m

Net Income

(51.8 m)(245.6 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

12.5 m1.6 m9.8 m27.6 m20.8 m19.3 m

R&D expense

57.8 m60.2 m11.5 m73.7 m72.3 m60.9 m82.9 m

General and administrative expense

6.7 m14.9 m13.6 m16 m16.8 m18.4 m20.7 m

Operating expense total

64.5 m75.1 m25.1 m89.7 m89.1 m79.3 m103.7 m

EBIT

(65.2 m)(68 m)(23.5 m)(79.9 m)(61.5 m)(58.5 m)(84.3 m)

EBIT margin, %

(545%)(1469%)(817%)(223%)(281%)(436%)

Pre tax profit

(67.6 m)(23.2 m)(78.5 m)(66 m)(57.5 m)(83.5 m)

Income tax expense

(63 k)594 k1.3 m

Net Income

(65 m)(66 m)(23.2 m)(71.1 m)(64.8 m)(56.9 m)(82.2 m)
USDFY, 2015FY, 2016

Cash

252.4 m187.9 m

Accounts Receivable

315 k13.3 m

Inventories

8.4 m26.5 m

Current Assets

951.8 m772.3 m

PP&E

42.1 m81.7 m

Goodwill

122.1 m221.3 m

Total Assets

1.4 b1.3 b

Accounts Payable

4.2 m4.4 m

Current Liabilities

119.7 m114.9 m

Additional Paid-in Capital

1.7 b1.9 b

Retained Earnings

(585.7 m)(831.2 m)

Total Equity

1.1 b1.1 b

Financial Leverage

1.3 x1.3 x
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

164.2 m39.5 m569.1 m316 m285.3 m223.4 m205.7 m

Accounts Receivable

9.3 m10.6 m8.8 m

Current Assets

400.7 m307.8 m1.2 b956 m974.6 m844.8 m779.5 m

PP&E

15.4 m28.7 m36.9 m45 m51.5 m57.7 m102.5 m

Goodwill

122.1 m122.1 m221.3 m221.3 m221.3 m221.3 m

Total Assets

476 m524.2 m1.5 b1.5 b1.5 b1.4 b1.3 b

Accounts Payable

866 k1.9 m3 m2.2 m3.2 m3.7 m3.2 m

Current Liabilities

137.4 m160.5 m149.4 m106.7 m143.7 m133 m122.6 m

Additional Paid-in Capital

740.3 m789.3 m1.6 b1.9 b1.9 b1.9 b1.9 b

Retained Earnings

(411.2 m)(477.2 m)(500.4 m)(656.8 m)(721.6 m)(778.5 m)(913.4 m)

Total Equity

329.1 m311.3 m1.1 b1.2 b1.2 b1.1 b1 b

Financial Leverage

1.4 x1.7 x1.3 x1.2 x1.3 x1.3 x1.3 x
USDFY, 2015FY, 2016

Net Income

(51.8 m)(245.6 m)

Depreciation and Amortization

2 k14.2 m

Accounts Receivable

33 k(13 m)

Accounts Payable

(2.7 m)3.7 m

Cash From Operating Activities

(103.6 m)(189.8 m)

Purchases of PP&E

(42 k)(56.2 m)

Cash From Investing Activities

(42 k)88.6 m

Cash From Financing Activities

66.5 m36.8 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(65 m)(66 m)(23.2 m)(71.1 m)(64.8 m)(56.9 m)(82.2 m)

Depreciation and Amortization

1 m

Accounts Receivable

9.3 m10.6 m8.8 m

Accounts Payable

(27 k)1.9 m3 m2.2 m3.2 m3.7 m3.2 m

Cash From Operating Activities

(21.6 m)

Purchases of PP&E

(2.3 m)

Cash From Investing Activities

(168.5 m)

Cash From Financing Activities

(1.7 m)
USDY, 2017

Revenue/Employee

35.8 k

Financial Leverage

1.3 x

Juno Therapeutics Operating Metrics

Juno Therapeutics's Patent Applications was reported to be 481 in FY, 2016
FY, 2016

Patents (US)

72

Patent Applications

481

Patents (foreign)

86

Juno Therapeutics Market Value History

Traffic Overview of Juno Therapeutics

Juno Therapeutics Online and Social Media Presence

Juno Therapeutics News and Updates

Venrock has raised $450 million for its eighth fund — just like its seventh fund

 Venrock, the 47-year-old venture firm that started as the venture arm of the Rockefeller family, has closed its eighth fund with $450 million, which longtime partner Bryan Roberts calls “not too big and not too small, but just about right” in a new blog post. Certainly, it’s an amount that the part…

Jeff Bezos, Mayo Clinic back anti-aging startup Unity Biotechnology for $116 million

 Every once in a while someone in Silicon Valley brings up the possibility of living forever, or at least a really long time, but first we’re going to need to figure out a way to enjoy all those extra years. Unity Biotechnology is a startup focusing on medicines to help us do that by slowing the eff…

Study of Juno Therapeutics Leukemia Treatment Is Allowed to Resume

The government said two deaths that prompted it to stop the study had been caused by a drug used in pretreatment, not the leukemia treatment.

Shares of Juno Therapeutics jump after FDA removes clinical hold on cancer drug trial

(Reuters) - Juno Therapeutics Inc said U.S. health regulators have removed a clinical hold on its cancer drug trial that was put in place last week following the death of three patients, sending its shares up about 28 percent in extended trading.

Study of Juno Therapeutics Cancer Treatment Allowed to Resume

A study of an experimental treatment for leukemia that was halted after two patients died has been allowed to resume after a modification.

Pharma Shares Drop After FDA Stops Cancer Therapy Trial for Patient Deaths

Juno Therapeutics was conducting the trial, but other firms also took a hit.

Juno Therapeutics Company Life and Culture

You may also be interested in